63 results on '"Graziano F"'
Search Results
2. Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort
3. Power-Laws hereditariness of biomimetic ceramics for cranioplasty neurosurgery
4. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients
5. Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer
6. Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients
7. Endogastric capsule for E-cadherin gene (CDH1) promoter hypermethylation assessment in DNA from gastric juice of diffuse gastric cancer patients
8. 2206P Detection of circulating KRAS4A and KRAS4B isoforms in patients with metastatic lung adenocarcinoma treated with pembrolizumab or chemotherapy plus pembrolizumab by liquid biopsy: Clinical impact and association with circulating PD-L1
9. Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype
10. Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs
11. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice
12. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes’ B colorectal cancer patients: how much evidence is enough?
13. Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
14. An endogastric capsule for measuring tumor markers ingastric juice: an evaluation of the safety and efficacy of a new diagnostic tool
15. T.06.10 EFFICACY AND SAFETY OF BIOSIMILARS OF ANTI-TNF-APLHA IN PAEDIATRIC-ONSET INFLAMMATORY BOWEL DISEASE: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD)
16. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)
17. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: Relationships with tumor recurrence and resistance to adjuvant chemotherapy
18. AF.57 SPOSAB ABP 501: A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501
19. PC.01.3 SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)
20. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer
21. Chemotherapy for advanced pancreatic cancer: It may no longer be ignored
22. OC.02.3 A PROPENSITY SCORE WEIGHTED COMPARISON OF VEDOLIZUMAB, ADALIMUMAB, AND GOLIMUMAB IN PATIENTS WITH ULCERATIVE COLITIS: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)
23. P-75 Retrospective comparison between FLOT perioperative chemotherapy vs surgery followed by adjuvant chemotherapy: Results from a multicenter analysis
24. PD-015 - Optimizing the use of first-line chemotherapy in metastatic colorectal cancer patients with mucinous histology. A multicenter, retrospective, combined analysis on 897 patients
25. Early onset inflammatory bowel diseases and biological therapy: Results from the Sicilian Network
26. A3 - Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial
27. A1* - Does bevacizumab plus chemotherapy matter in metastatic colorectal cancer patients with mucinous histology? A multicenter, retrospective analysis on 685 patients
28. 2* - Dihydropyrimidine dehydrogenase (DPYD) gene polymorphisms profiling in colon cancer patients treated with adjuvant chemotherapy in the randomized phase III TOSCA trial
29. Towards achieving a state of reversible HIV-1 latency in primary monocyte-derived macrophages (MDM) by M1 polarization
30. Fatty liver disease and abdominal pain with diarrhea hide hypobetalipoproteinemia
31. Obesity and homocysteine level in children, preliminary data
32. E49 - Glucose metabolism enzymes gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer (CRC)
33. E23 - DEBIRI and cetuximab (DEBIRITUX) as a secondline treatment for unresectable colorectal liver metastases (UCLM): results of a phase II trial exploring a new sequence
34. 2397 Evaluation of MET using FISH, IHC, or mass spectrometry as a prognostic biomarker in patients with gastroesophageal cancer
35. 251 TS, MTHFR AND XRCC1 GENETIC VARIANTS INFLUENCE THE OUTCOME OF MDS PATIENTS IRRESPECTIVELY OF IPSS RISK
36. 576P - Pharmacogenetic Profiling for Toxicity of Oxaliplatin and Fluoropyrimidines. Final Report from an Ancillary Protocol to the Tosca (Three or Six Colon Adjuvant) Trial
37. Genic correlation between the expression of EZH2 and the degree of liver damage in NAFLD
38. PO25 GASTROINTESTINAL SYMPTOMS AND FABRY DISEASE
39. CO14 POST-INFECTIOUS FUNCTIONAL GASTROINTESTINAL DISORDERS IN CHILDREN: A MULTICENTER PROSPECTIVE STUDY
40. 1681P - The Role of Macrophages Polarization in Predicting Prognosis in Radically Resected Gastric Cancer
41. EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle
42. PP68 RECURRENT ABDOMINAL PAIN AND FABRY DISEASE
43. Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients
44. High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice
45. PA31 RELATIONSHIP BETWEEN CELIAC DISEASE AND ORAL PATHOLOGIES IN CHILDREN
46. PP29 FUNCTIONAL ABDOMINAL PAIN DISORDERS IN CHILDREN: ROME II VS ROME III CRITERIA
47. 6115 VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
48. 6113 BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients
49. State and trait anxiety in children's mothers with coelic diseases: Preliminary data
50. 210 An analysis of CDH1 −160 C/A promoter polymorphism and the risk of diffuse gastric cancer in Italy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.